Close Menu

Lung Cancer

News and reporting on lung cancer.

Signal filed its suit against Med BioGene earlier this month alleging a breach of agreement, violation of a confidentiality agreement, and misuse of proprietary information, among other charges.

According to the company's earnings statement, MDxHealth's product and service revenues nearly doubled – from €1 million in 2009 to €2 million in 2010 – due to several companion diagnostics deals and biomarker licensing agreements inked with major drug companies.

New Releases: Feb 23, 2011

Premium

Sigma Life Science's new cancer cell lines

Signal has alleged that Med BioGene breached the provisions in a term sheet inked between the two companies regarding an exclusive, worldwide license for Med BioGene's LungExpress Dx test.

The device, which the scientists are developing under a two-year, €1.3 million grant from Germany's Federal Ministry of Education and Research, uses cytometric bead arrays to quantitate protein biomarkers in patients' exhaled breath condensate.

The diagnostic is being developed using a new peptoid-based technique for detecting disease-specific antibodies that could prove broadly useful as a protein biomarker discovery tool, said a researcher.

BU will use grants from NCI and DOD with partners at UCLA, Vanderbilt, and MD Anderson to develop early-stage lung cancer diagnostics.

The test is intended both for early screening purposes and the differential diagnoses of lung nodules detected during CT scans and x-rays. SomaLogic has partnered with Quest Diagnostics to commercialize the test, with a lab-developed version slated for launch next year.

The funding will go toward ongoing commercialization efforts for VeriStrat, the company's protein biomarker-based companion diagnostic for non-small cell lung cancer.

The funding will be used by Insight to develop companion diagnostics for lung cancer.

Pages

Kelvin Droegemeier, the director of the White House Office of Science and Technology Policy, is the new acting director of the US National Science Foundation.

An opinion piece at the Guardian discusses the state of SARS-CoV-2 testing in the UK.

Wired reports the University of California, Berkeley's Innovative Genomics Institute has transformed itself into a diagnostic lab to run SARS-CoV-2 tests.

In Nature this week: direct-capture Perturb-seq approach for combinatorial single-cell CRISPR screens, potential uses of genome-editing in breeding crops, and more.